CLINICAL EVALUATION OF A NEW PHENOTHIAZINE TRANQUILIZER, FLUPHENAZINE (PROLIXIN)
Abstract
Of the patients treated with fluphenazine, 141 of the 166 who were evaluated (85%) improved, 23 responded poorly, and 24 were for appropriate reasons not evaluated. The average dose was 5 mg. on admission, 5 mg. the next morning and 2.5 mg. thereafter as a single morning dose. Extrapyramidal effects were seen in patients receiving higher doses (5 to 10 mg. daily) but these were controllable by reducing the dosage.
Fluphenazine is an effective tranquilizer and is the most potent of the phenothiazines previously employed here, being about 25 times as potent as chlorpromazine. The rapid and sustained action of the drug and its administration as a single daily dose are distinctly advantageous.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
